OHSU Knight Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, OHSU Knight Cancer Institute sits in the top decile of US sponsors by registered trial count (#150 of 15,742 sponsors by registered trial count).
OHSU Knight Cancer Institute: 211 sponsored US clinical trials, 35 recruiting.
OHSU Knight Cancer Institute sponsors 211 registered US clinical trials on ClinicalTrials.gov, 35 of them currently recruiting, and 94 completed. 5 of these trials are in Phase 3-4 (later-stage) and 114 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 6 trials.
Top-decile sponsor footprint
OHSU Knight Cancer Institute ranks in the top decile of sponsors by registered trial count (#150 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
94 of 149 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
211 total, page 3 of 5
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
NCT03009201
Contrast Enhanced MRI of the Prostate
NCT02245282
Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease
NCT02890979
Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
NCT02503358
Exercise and Nutrition Program in Improving Physical Activity and Dietary Behavior in Non-Active, Overweight, or Obese Latinas
NCT03028935
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
NCT02736617
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT02427841
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
NCT02779283
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
NCT02504359
Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer
NCT02501759
Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma
NCT02359097
Computer-Based Behavior Change Guide in Increasing Physical Activity in Patients With Prostate Cancer Who Have Received Androgen Deprivation Therapy
NCT02869412
Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
NCT02092324
CATCH-UP Intervention in Increasing Cancer Screening and Prevention Care in Uninsured Patients at Community Health Centers
NCT02355262
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
NCT02099864
Esophageal Cytology With FISH in Detecting Esophageal Cancer
NCT02100189
DCE MRI in Patients With Pancreatic Cancer
NCT02070705
Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
NCT02050919
Vascular Response to Brachytherapy Using Functional OCT
NCT01955941
CROSSROAD II: Activating Rural Clinics and Women With Disabilities to Improve Cancer Screening
NCT01773980
Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT01913015
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide
NCT02228265
Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer
NCT01780701
Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer
NCT01748942
Vietnamese Women's Health Project III
NCT01704235
Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)
NCT01635413
Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01689987
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
NCT01620216
MRI Assessment of Leukemia Response to Therapy
NCT01537159
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
NCT01532687
Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT01498978
Therapy to Prevent Sexual Pain in Breast Cancer Survivors
NCT01539317
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
NCT01441882
Magnetic Resonance Imaging (MRI) in the Assessment of Head and Neck Squamous Cell Carcinoma (HNSCC) Response
NCT00994201
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma
NCT01397591
Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy
NCT01422408
Comparing Warm Versus Cool Temperature Water During Colonoscopy
NCT01322724
Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis
NCT01556503
Fibrin Sealant in Preventing Fluid Build Up During Surgery in Patients Undergoing Breast Reconstruction
NCT01649505
Sulforaphane in Treating Patients With Recurrent Prostate Cancer
NCT01228084
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
NCT01253642
Abraxane/Bevacizumab
NCT01821859
Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy
NCT00843167
DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors
NCT00978562
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT01005914
Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma
NCT00822848
Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy
NCT00769093
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
NCT00764517
Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy
NCT01031953
Blood Samples From Patients on a Clinical Trial to CINV During HSCT
NCT00900068
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 41 |
| Phase 2 | 73 |
| Phase 3 | 2 |
| Phase 4 | 3 |
Therapeutic Areas
What is open in the OHSU Knight Cancer Institute pipeline
35 recruiting of 211 indexed (17% open); 94 completed (45%).
Phase mix: 5 late (III/IV) vs 114 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
OHSU Knight Cancer Institute: open-pipeline peers nationwide
Peers matched on 211 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
OHSU Knight Cancer Institute sits below the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 211 trials (± recruiting share)
- MedImmune · 210 trials · 0% recruiting
- University of Louisville · 217 trials · 21% recruiting
- Florida State University · 219 trials · 21% recruiting
- Penn State University · 219 trials · 17% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Rush University Medical Center · 17% recruiting · 320 trials
- Massachusetts General Hospital · 17% recruiting · 2,032 trials
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
Related
What to do with this OHSU Knight Cancer Institute page
211 registered trials is a research-attention snapshot, not an endorsement of OHSU Knight Cancer Institute or any single study.
- 35 of OHSU Knight Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition OHSU Knight Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
OHSU Knight Cancer Institute pipeline card: 211 registered trials from official public datasets.Report a data error.